Wenlan Zhang, MD
Retina Specialist · Portland, ORNPI 1982961405
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Genentech USA, Inc. at 48.5% of the total. 2025 is the largest year on record at $560, 7.4 times the $76 reported in 2019. That places this record below the midpoint for retina specialist clinicians in OR, where the typical reported total is $1,870.
Across 11 payments — averaging $120.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$644
- Regeneron$464
- Regeneron Healthcare Solutions, Inc.$220
What the payments were for
- Food & beverage$1,327100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 5 | $644 |
| Regeneron | 4 | $464 |
| Regeneron Healthcare Solutions, Inc. | 2 | $220 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,327 in reported general payments places this provider in the 45th percentile of 36 retina specialist providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 192 | $7,682 |
| Difluprednate | 32 | $4,007 |
| Ketorolac Tromethamine | 137 | $3,132 |
| Ofloxacin | 60 | $697 |
| Brimonidine Tartrate | 11 | $611 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $277 |
| ErythromycinErythromycin Base | 20 | $236 |
| Timolol Maleate | 40 | $235 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Portland
- Brian Chan KaiPortland$155K
- Brandon LujanPortland$33K
- Andreas LauerPortland$17K
- Sirichai PasadhikaPortland$6K
- David WilsonPortland$5K
- Harpal SandhuPortland$3K
- Aristomenis ThanosPortland$3K
- Michael LeePortland$3K
- Paul TlucekPortland$2K
- Kavita BhavsarPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.